Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "ZS"

19 News Found

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps
Drug Approval | October 21, 2025

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation


AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps
News | September 23, 2025

AstraZeneca’s Tezspire recommended for approval in the EU for chronic Rhinosinusitis with nasal polyps

Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent


Tezspire approved in the EU for the treatment of severe asthma
Drug Approval | September 21, 2022

Tezspire approved in the EU for the treatment of severe asthma

First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations


ZS and Quartic to accelerate digitalization in life sciences and healthcare
Digitisation | May 18, 2022

ZS and Quartic to accelerate digitalization in life sciences and healthcare

ZS and Quartic will collaborate to help drive resilience, increase adoption of Industry 4.0 and improve predictive decision-making across manufacturing


New data reinforces efficacy of Tezspire
Biotech | February 27, 2022

New data reinforces efficacy of Tezspire

These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting


Pharma tops India’s exports from SEZs
News | September 01, 2021

Pharma tops India’s exports from SEZs

As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational


BioNxt secures Eurasian patent for breakthrough sublingual MS therapy
News | November 24, 2025

BioNxt secures Eurasian patent for breakthrough sublingual MS therapy

The Eurasian Patent Organization (EAPO) has granted Patent, protecting the company’s sublingual delivery technology for anticancer drugs used to treat autoimmune and neurodegenerative diseases


Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
News | September 24, 2025

Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion


Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025
News | May 23, 2025

Merck KGaA, Darmstadt, Germany, Showcases Innovation at ASCO 2025

Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025